This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Febbraio, M. Search for Related Content PubMed Articles by Febbraio, M. Related Collections Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:1209.)
© 2008 American Heart Association, Inc.

Editorials

CD36 Goes Native

Maria Febbraio

From the Cleveland Clinic, Lerner Research Institute, Department of Cell Biology, Cleveland, Ohio.

Correspondence to Maria Febbraio, Cleveland Clinic, Lerner Research Institute, Department of Cell Biology, 9500 Euclid Avenue, NC 1-139, Cleveland, Ohio 44195. E-mail febbram@ccf.org

An extract of the first 250 words of the full text is provided, because this article has no abstract.

There’s a saying that goes: "everything old is new again," and I am reminded of this by the article by Luangrath et al¹ in this issue of Arteriosclerosis, Thrombosis and Vascular Biology. Not that this article shows old data, but that what was old, now cast in a different light, leads to new ideas and hypotheses. Just about 10 years ago, Calvo et al² showed that human CD36 bound native LDL, HDL, and VLDL. Later, Connelly et al³ found that CD36 could mediate selective cholesterol ester uptake from LDL. These were both intriguing findings, but without in vivo data there was a question of relevance. Since then, most studies have focused on CD36 recognition of aberrant lipoproteins, and a role for CD36 in native lipoprotein biology has been overshadowed. With this article, and several others recently published, the spotlight has begun to shift to potential functional roles of CD36 in native lipoprotein biology.

See accompanying article on page 1290

CD36 was first identified as a platelet glycoprotein (GP) and originally primarily thought of as a receptor for thrombospondin-1, and involved in adhesion. As the oxidation theory of lipoprotein modification gained traction as an underlying mechanism for atherogenesis, interest in receptors for oxidized LDL (oxLDL) increased. The observation that CD36 was an oxLDL receptor was the catalyst for many to probe the role of CD36 in atherosclerosis. Further work to define the ligand on oxLDL that was recognized by CD36 implicated the lipid of the lipoprotein, and later work identified . . . [Full Text of this Article]

Related Article:

Mouse CD36 Has Opposite Effects on LDL and Oxidized LDL Metabolism In Vivo

Vilayphone Luangrath, Mathieu R. Brodeur, David Rhainds, and Louise Brissette
Arterioscler Thromb Vasc Biol 2008 28: 1290-1295. [Abstract] [Full Text] [PDF]